Foundation Medicine to Develop Dx for Agios Cancer Therapeutics | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine and Agios Pharmaceuticals today announced a deal to develop diagnostics for the biopharmaceutical firm's drug candidates.

Under the terms of the deal, the partners seek to identify genomic alterations, which can be used to pick out those patients most likely to respond to Agios' new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. Using this information, Foundation and Agios will then develop and potentially commercialize diagnostics for the drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.